Literature DB >> 19559478

Dexamethasone-induced apoptosis and up-regulation of Bim is dependent on glycogen synthase kinase-3.

Ulla Nuutinen1, Antti Ropponen, Sanna Suoranta, Jonna Eeva, Mine Eray, Riikka Pellinen, Jarmo Wahlfors, Jukka Pelkonen.   

Abstract

Glucocorticoids are commonly used in the treatment of lymphoid malignancies. In this study, we show that apoptosis induced by dexamethasone (Dex), a synthetic glucocorticoid, was dependent on mitochondria, since overexpression of Bcl-X(L) prevented Dex-induced apoptotic changes. Dominant negative (DN) caspase-9 also prevented Dex-induced apoptotic changes including the loss of mitochondrial membrane potential indicating that caspase-9 controls mitochondrial changes. In addition, we evaluated the role of glycogen synthase kinase (GSK3) in Dex-induced apoptosis. Inhibition of GSK3 attenuated Dex-induced up-regulation of Bim, loss of mitochondrial membrane potential, release of cyt c and DNA fragmentation. These results indicate that GSK3 contributes to Dex-induced apoptosis by controlling up-regulation of Bim.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19559478     DOI: 10.1016/j.leukres.2009.06.004

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

1.  Glycogen synthase kinase-3β is involved in ligand-dependent activation of transcription and cellular localization of the glucocorticoid receptor.

Authors:  Camila Rubio-Patiño; Claudia M Palmeri; Alba Pérez-Perarnau; Ana M Cosialls; Cristina Moncunill-Massaguer; Diana M González-Gironès; Lluís Pons-Hernández; José M López; Francesc Ventura; Joan Gil; Gabriel Pons; Daniel Iglesias-Serret
Journal:  Mol Endocrinol       Date:  2012-07-06

2.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

3.  Glucocorticoids for mitochondrial disorders.

Authors:  Josef Finsterer; Marlies Frank
Journal:  Singapore Med J       Date:  2015-02       Impact factor: 1.858

4.  Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes.

Authors:  Lindsay K Smith; John A Cidlowski
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

5.  Genomic duplication and overexpression of TJP2/ZO-2 leads to altered expression of apoptosis genes in progressive nonsyndromic hearing loss DFNA51.

Authors:  Tom Walsh; Sarah B Pierce; Danielle R Lenz; Zippora Brownstein; Orit Dagan-Rosenfeld; Hashem Shahin; Wendy Roeb; Shane McCarthy; Alex S Nord; Carlos R Gordon; Ziva Ben-Neriah; Jonathan Sebat; Moien Kanaan; Ming K Lee; Moshe Frydman; Mary-Claire King; Karen B Avraham
Journal:  Am J Hum Genet       Date:  2010-06-17       Impact factor: 11.025

6.  Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells.

Authors:  Tuoen Liu; Zhiqiang Fei; Kalyan J Gangavarapu; Senyo Agbenowu; Alok Bhushan; James C K Lai; Christopher K Daniels; Shousong Cao
Journal:  Leuk Res       Date:  2013-07-18       Impact factor: 3.156

Review 7.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15

8.  Overcoming glucocorticoid resistances and improving antitumor therapies: lipid and polymers carriers.

Authors:  C Martín-Sabroso; A J Moreno-Ortega; J Aparicio-Blanco; A I Fraguas-Sánchez; M F Cano-Abad; A I Torres-Suárez
Journal:  Pharm Res       Date:  2014-09-12       Impact factor: 4.200

9.  Dexamethasone destabilizes Nmyc to inhibit the growth of hedgehog-associated medulloblastoma.

Authors:  Vivi M Heine; Markus Priller; Jason Ling; David H Rowitch; Ulrich Schüller
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

10.  Magnetic Fe₃O₄ nanoparticles and chemotherapy agents interact synergistically to induce apoptosis in lymphoma cells.

Authors:  Hongmei Jing; Jing Wang; Ping Yang; Xiaoyan Ke; Guohua Xia; Baoan Chen
Journal:  Int J Nanomedicine       Date:  2010-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.